Kate Therapeutics
Dragos G. has extensive experience in the field of biophysical methods and gene therapy formulation development, with a focus on chromatographic methods for protein and antibody analysis. Dragos has held various scientific positions at companies such as Kate Therapeutics, PhenoTarget Biosciences, and Locanabio. Prior to their industry roles, Dragos worked as a postdoc at The Scripps Research Institute, focusing on enantioselective processes and origins of life research. Dragos holds a PhD from Aix-Marseille University and a Micro-MBA from the University of California, San Diego.
Kate Therapeutics
Kate Therapeutics (KateTx) is a patient-focused biotechnology company developing adeno-associated virus (AAV)-based gene therapies to treat genetically defined muscle and heart diseases. The company is applying novel technology platforms that directly address the key limitations of current gene therapies, including tissue-specific delivery and gene regulation. These breakthroughs have the potential to improve the efficacy and safety of gene therapies and enable the pursuit of a broader set of targets that are otherwise difficult to drug with current technologies.